Know Cancer

forgot password

Preoperative Hormone Therapy for Pre- and Postmenopausal Women With ER Positive Breast Cancer: A Double Blind Randomized Parallel Group Phase II Trial, Comparing the Effect of 2 Weeks of Preoperative Estetrol With Placebo

Phase 2
18 Years
70 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Preoperative Hormone Therapy for Pre- and Postmenopausal Women With ER Positive Breast Cancer: A Double Blind Randomized Parallel Group Phase II Trial, Comparing the Effect of 2 Weeks of Preoperative Estetrol With Placebo

The study is designed as a single-center, randomized, double-blind, placebo-controlled study
in pre- and postmenopausal women who will undergo surgery for breast cancer. Subjects will
either receive estetrol or placebo during a 2 week treatment period.

Several biological markers, such as a cellular growth marker and cell death markers, will be
assessed in the tumor tissue and surrounding normal tissue before and after the treatment
period. In addition, receptor studies will be performed. During the 2 week interval between
diagnosis of breast cancer and surgical resection, no therapy for breast cancer is usually

Inclusion Criteria:

1. Histologically confirmed diagnosis of early invasive primary breast cancer
(clinically stage I or II; T1 - T2; N0-1; M0, which requires surgery).

2. The malignant tumor must be estrogen receptor (ER) positive as determined by the
local pathologist. Weak, intermediate and strong staining is considered appropriate
for inclusion.

3. The breast tumor size must be adequate for core cut biopsy to obtain sufficient
amount of tissue for gene and protein expression analysis.

4. Subjects will be either pre- or post-menopausal.

- The postmenopausal study group has been defined as follows: not older than 70
years of age and a natural menopause with the last menstrual bleeding at least
12 months before the start of the study. If the date of last menstruation is
uncertain because of perimenopausal HRT or in case of past hysterectomy with
intact ovaries, then the subject must have appropriate FSH and Estradiol (E2)
levels (FSH > 40 International Units (IU)/L and E2 < 20 pg/ml (=73.40 pmol/l))
after completion of a HRT wash-out according to exclusion criterion 2 and 3.

- The premenopausal study group has been defined as follows: At least 18 years
and not older than 50 years of age with at least one spontaneous menstrual
bleeding during the last 6 months, combined with an FSH level below 10 IU/L.
Before treatment starts a pregnancy test will be performed that has to be
negative. If appropriate a barrier method of contraception has to be used for
the duration of the study. The criteria for perimenopausal HRT wash-out are
according to exclusion criterion 2 and 3.

5. BMI must be between 18 and 32 kg/m2.

6. The patient must provide voluntary written informed consent.

Exclusion Criteria:

1. Any serious disease (e.g. severe liver or renal disease), clinically significant
abnormal laboratory values (e.g. abnormal serum liver enzyme concentrations above the
upper safety limit) or any other clinically significant abnormalities which, in the
investigator's opinion, may lead to adverse events during the course of the trial

2. Previous use of estrogen/progestogen within:

- 6 months for depot preparations.

- 8 weeks for oral preparations or progestogen containing IUD.

- 4 weeks for transdermal preparations

3. Use of hormone containing implant at any time

4. Contraindications for using steroids:

- A history of, or existing thromboembolic, cardiovascular or cerebrovascular

- A history of, or existing conditions predisposing to, or being prodromi of, a

- A known defect in the blood coagulation system (e.g. deficiencies in AT-III,
protein C, S, and APC resistance).

- A medical history positive for the presence of more than one risk factor for
vascular disease (e.g. dyslipoproteinemia; diabetes mellitus;
hyperhomocysteinemia; systemic lupus erythematosus; chronic inflammatory bowel
disease; smoking; venous thromboembolism in sibling or parent below the age of
50, or arterial disease in sibling or parent below the age of 30-35).

- Hypertension, i.e. systolic blood pressure >160 mm Hg and/or diastolic blood
pressure >100 mm Hg.

- Disturbance of liver function: cholestatic jaundice, a history of jaundice of
pregnancy or jaundice due to previous estrogen use, Rotor syndrome and
Dubin-Johnson syndrome.

- Any previous hormone-related malignancies within the last 5 years. History or
presence of endometrial cancer. Exceptions are basaliomas of the skin and
intraepithelial cervical neoplasias (CIN1-3).

- Undiagnosed vaginal bleeding.

- Porphyria.

- A history during pregnancy or previous estrogen use of severe pruritus, herpes
gestationis or deterioration of otosclerosis.

5. Presence of significant allergy

6. Administration of investigational drugs within 3 months before start study medication

7. A history of (within 12 months) alcohol or drug abuse.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

To compare changes in the expression of a proliferation marker in malignant breast tissue after treatment with E4 or Placebo.

Outcome Time Frame:

14 days

Safety Issue:


Principal Investigator

Christian F Singer, MD, MPH

Investigator Role:

Principal Investigator

Investigator Affiliation:

Medical University of Vienna


Austria: Agency for Health and Food Safety

Study ID:




Start Date:

April 2007

Completion Date:

March 2010

Related Keywords:

  • Breast Cancer
  • Breast cancer (Estrogen Receptor positive)
  • Breast Neoplasms